{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(12)"],"submitter":["Verset G"],"funding":["Merck &amp; Co., Inc., Kenilworth, NJ","Merck Sharp &amp; Dohme Corp."],"pubmed_abstract":["<h4>Purpose</h4>KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior systemic therapy.<h4>Patients and methods</h4>KEYNOTE-224 was an open-label, multicountry phase II trial. Eligible patients in cohort 2 had advanced HCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for ≤2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease c"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["2547-2554"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9784157"],"repository":["biostudies-literature"],"pubmed_title":["Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial."],"pmcid":["PMC9784157"],"pubmed_authors":["Hatogai K","Wang A","Chan SL","Siegel AB","Knox JJ","Qin S","Zhu AX","Borbath I","Zagonel V","Kudo M","Palmer DH","Verset G","Sarker D","Chisamore M","Karwal M","Kardosh A","Edeline J","Vogel A","Ogasawara S","Stal P","Verslype C","Cattan S","Daniele B","Van Vlierberghe H","Cheng AL","Finn RS"],"additional_accession":[]},"is_claimable":false,"name":"Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.","description":"<h4>Purpose</h4>KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with advanced HCC and no prior systemic therapy.<h4>Patients and methods</h4>KEYNOTE-224 was an open-label, multicountry phase II trial. Eligible patients in cohort 2 had advanced HCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for ≤2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease c","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-28T03:45:32.627Z","creation":"2025-04-06T00:53:05.483Z"},"accession":"S-EPMC9784157","cross_references":{"pubmed":["35421228"],"doi":["10.1158/1078-0432.CCR-21-3807"]}}